Fig. 4From: Exploring treatment with Ribociclib alone or in sequence/combination with Everolimus in ER+HER2−Rb wild-type and knock-down in breast cancer cell linesIsobologram plots and CI Values for combination Rib/Eve treatments. On the lower left of the hypotenuse synergism, on the hypotenuse additive effect, and on the upper right of the hypotenuse antagonism. Synergistic activity of Rib/Eve was assessed by CompuSyn software. CI = 1, < 1 and > 1 indicates additive effect, synergism and antagonism, respectively, in Rib/Eve-treated Rb WT (a) and KD (b) MCF-7 cellsBack to article page